Alfacalcidol is a synthetic analogue of vitamin d3 that is converted to the active form of calcitriol in the body. It is used therapeutically to manage secondary hyperparathyroidism in patients with chronic kidney disease. By providing a more stable and readily absorbable form of vitamin d, it supports calcium and phosphate homeostasis. The active metabolite enhances intestinal absorption of calcium and phosphorus, thereby correcting mineral deficiencies. In the liver and kidney, Alfacalcidol undergoes hydroxylation to form calcitriol, the biologically active isoform. Calcitriol binds to the vitamin d receptor in target tissues, initiating transcription of genes involved in calcium transport. This receptor activation leads to increased expression of calcium-binding proteins and phosphate transport channels. The overall pharmacological effect is the restoration of adequate mineral levels without the need for high-dose vitamin d supplementation.

Alfacalcidol is a synthetic vitamin d analog used clinically to support calcium regulation. It enhances intestinal absorption of calcium and phosphorus by activating vitamin d receptors in gut cells. Once metabolized it functions as calcitriol which binds to nuclear receptors to modulate gene expression. This leads to increased transcription of proteins that transport calcium across the intestinal mucosa. The resulting rise in serum calcium helps maintain bone mineralization and supports skeletal health. Alfacalcidol is prescribed primarily for patients with secondary hyperparathyroidism and certain osteodystrophies. Its therapeutic effect stems from restoring normal vitamin d activity in individuals with impaired renal conversion of vitamin d. By mimicking the active hormone it adjusts calcium and phosphate balance without directly stimulating parathyroid hormone release.

Alfacalcidol is generally well tolerated when taken as prescribed. Some patients may experience mild gastrointestinal discomfort such as nausea or constipation. Headache and dizziness have also been reported in occasional cases. Skin reactions like rash or itching can occur but are usually transient. Elevated blood calcium levels may lead to symptoms such as fatigue or increased thirst. In rare instances, muscle weakness or joint pain have been observed. These effects are typically mild and resolve without intervention. Overall the medication's safety profile remains favorable in most clinical settings.

Alfacalcidol can occasionally cause mild nausea or upset stomach. Headache and dizziness have been reported in a small number of patients. Skin reactions such as rash or itching may appear occasionally. Some people experience fatigue or a feeling of weakness. Elevated blood calcium levels can lead to increased thirst and frequent urination. Rarely, constipation or diarrhea may occur. These effects are generally mild and often resolve without medical intervention.